The company disclaims anyintent or obligation to update these forward-looking statements.Key Words: Stem Cells, Biotechnology, Parthenogenesis International Stem Cell CorporationKenneth C. Aldrich, Chairman, orThe Investor Relations Group212-825-3210Investor Relations:Adam S. Forward-looking statements involve risks anduncertainties, including, without limitation, risks inherent in the developmentand/or commercialization of potential products, uncertainty in the results ofclinical trials or regulatory approvals, need and ability to obtain futurecapital, application of capital resources among competing uses, and maintenanceof intellectual property rights. Anystatements that are not historical fact (including, but not limited tostatements that contain words such as "will," "believes," "plans,""anticipates," "expects," "estimates") should also be considered to beforward-looking statements. For more information, visit the ISCO website at:.
To subscribe to receive ongoing corporate communications please click on thefollowing link: http:// FORWARD-LOOKING STATEMENTS:Statements pertaining to anticipated future financial and/or operating results,future growth in research, technology, clinical development and potential jointventure and other opportunities for the company and its subsidiary, along withother statements about the future expectations, beliefs, goals, plans, orprospects expressed by management constitute forward-looking statements. ISCO`s technology,Parthenogenesis, results in the creation of pluripotent human stem cell linesfrom unfertilized human eggs. ISCO scientists have created the firstParthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source oftherapeutic cells that will minimize immune rejection after transplantation intohundreds of millions of individuals of differing sexes, ages and racial groups.These advancements offer the potential to create the first true "Stem Cell Bank"and address ethical issues by eliminating the need to use or destroy fertilizedembryos. ISCO also produces and markets specialized cells and growth mediaworldwide for therapeutic research through its subsidiary Lifeline CellTechnology. "We are pleased that wehave secured a financing source that will be available to us at the time of ourown choosing over the next year." For more news and information on International Stem Cell Corporation pleasevisit where you can find the CEO`s video, a fact sheeton the company, investor presentations, and more.ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):International Stem Cell Corporation is a California biotechnology companyfocused on developing therapeutic and research products. The total exercise value of warrants issued will equal135% of the drawdown amount. Dividends on the Preferred Stock are payable inadditional shares of non-convertible Preferred Stock at the rate of 10% perannum.
Funds will be drawn down through the issuance of Series EPreferred Stock (the "Preferred Stock"). The Preferred Stock will not beconvertible into common stock and may be redeemed by the Company after one year.Each issue of Preferred Stock will be accompanied by the issuance of five-yearwarrants to purchase common stock at 100% of the closing price of the company`scommon stock on the day prior to the date the company gives notice of itselection to draw funds. "The flexibility of this financing will add greatly to our financial strength,"commented Kenneth Aldrich, CEO and Chairman of ISCO. A commitment fee of $250,000, payable in shares of common stock, was madeto the Investor. OCEANSIDE, Calif.--(Business Wire)--International Stem Cell Corporation (OTCBB:ISCO), has entered into a definitiveagreement for a $5 million investment commitment (the "Investment") with abiotechnology-focused fund (the "Investor") that has offices in New York andCalifornia. For more information: or 1 866-581-3596.Terms and Conditions:* Airfares displayed above are one way based on round trip purchase,non-refundable and subject to availability.Fare doesn't include governmentfees and taxes of up to $164 and a $2.50September 11th Security fee.
The Company may draw down funds from the Investor as it finds a need, but is notobligated to do so. Proceeds of theinvestment provide a valuable addition to the company`s capital structure.Together with the private capital already committed to the company and itsinternally generated revenue, these funds are expected to provide the capitalneeded by ISCO for the balance of 2009 and a significant amount of the capitalexpected to be needed in 2010. The Investment will be used to fund operations and working capitalneeds of the company and expand its scientific research. OpenSkies reserves the right to rescind this offer at any time.Othersignificant restrictions may apply. See for full details.SOURCEOpenSkiesMarissa Wolf for OpenSkies, +1-212-850-5629, .